Surgery in practice and science · 2026
Tranexamic acid in radical cystectomy: a systematic review and meta-analysis.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fereidooni Fatemeh, Dehbozorgi Masoud, Khalilzadeh Bonab Davoud, Shafiee Arman, Mirhosseini Fatemeh, Goodarzi Saba
Аннотация
BACKGROUND: Radical cystectomy is associated with substantial blood loss and transfusion requirements, raising the potential role of tranexamic acid (TXA) to mitigate these risks. However, its effectiveness and safety in this context remain to be fully established.
METHODS: A comprehensive search of PubMed, Embase, Web of Science, and Scopus from inception to May 19, 2025, identified studies involving adult patients undergoing cystectomy (partial or radical) comparing TXA with placebo, no treatment, or alternative hemostatic agents.
RESULTS: Four studies (1 RCT, 3 cohort studies) with sample sizes ranging from 64 to 936 patients were included. TXA significantly reduced estimated blood loss (SMD = -0.11; 95% CI: -0.21, -0.01; p = 0.03) and total transfusion volume (SMD = -0.28; 95% CI: -0.54, -0.02; p = 0.04). The odds of receiving any transfusion decreased by 52% (OR = 0.48; 95% CI: 0.30, 0.77; p = 0.002), with postoperative transfusion reduction particularly notable (OR = 0.32; 95% CI: 0.16, 0.63; p < 0.001). TXA showed no significant effect on intraoperative transfusion needs (OR = 0.95; p = 0.79) or perioperative hemoglobin change (SMD = 0.17; p = 0.08). Importantly, TXA did not increase VTE risk (OR = 1.49; p = 0.16) and was associated with a lower postoperative mortality in pooled analyses (OR = 0.62; 95% CI: 0.47, 0.82; p = 0.001).
CONCLUSIONS: Tranexamic acid appears effective in reducing blood loss and transfusion requirements during cystectomy, with no evidence of increased VTE risk and a potential survival benefit.
METHODS: A comprehensive search of PubMed, Embase, Web of Science, and Scopus from inception to May 19, 2025, identified studies involving adult patients undergoing cystectomy (partial or radical) comparing TXA with placebo, no treatment, or alternative hemostatic agents.
RESULTS: Four studies (1 RCT, 3 cohort studies) with sample sizes ranging from 64 to 936 patients were included. TXA significantly reduced estimated blood loss (SMD = -0.11; 95% CI: -0.21, -0.01; p = 0.03) and total transfusion volume (SMD = -0.28; 95% CI: -0.54, -0.02; p = 0.04). The odds of receiving any transfusion decreased by 52% (OR = 0.48; 95% CI: 0.30, 0.77; p = 0.002), with postoperative transfusion reduction particularly notable (OR = 0.32; 95% CI: 0.16, 0.63; p < 0.001). TXA showed no significant effect on intraoperative transfusion needs (OR = 0.95; p = 0.79) or perioperative hemoglobin change (SMD = 0.17; p = 0.08). Importantly, TXA did not increase VTE risk (OR = 1.49; p = 0.16) and was associated with a lower postoperative mortality in pooled analyses (OR = 0.62; 95% CI: 0.47, 0.82; p = 0.001).
CONCLUSIONS: Tranexamic acid appears effective in reducing blood loss and transfusion requirements during cystectomy, with no evidence of increased VTE risk and a potential survival benefit.